DTC founder, Sarah, named a Vanier Scholar




Ovarian cancer is known as the silent killer because people with ovaries often can have the disease for a long time before it is detected. This delay makes treatment difficult: patients can undergo surgery, chemotherapy and radiation. These treatments are harsh and have many side effects. New treatments called immunotherapies work differently, aiming to boost or activate a person’s immune system to allow them to fight cancer. These therapies are effective with lower toxicity and are quickly becoming a major pillar in cancer treatment. Unfortunately, though, existing immunotherapeutic strategies have not translated to successful approaches to treat ovarian cancer. We think that we need to better understand immune interactions with ovarian cancer to build better, more effective immunotherapies for ovarian cancer.


Read it here at Dal News.